Study ID: Amgen GLAGOV 20120153 IVUS

A Double-Blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization


The purpose of this research study is to look at the changes in the fatty deposits in the walls of the blood vessels of the heart and blood levels of ¿good¿ and ¿bad¿ cholesterol when AMG 145, an investigational drug, is taken in addition to current medical therapy including ¿statins,¿ which are medications for the treatment of abnormal cholesterol blood levels. Participants in this study are undergoing coronary catheterization. In this study, the effects of AMG 145 will be determined by an intravascular ultrasound (IVUS) procedure that measures the amount of fatty deposits in the arteries of your heart.

Fargo Region
Principal Investigator:
Thomas Haldis D.O.
Phase III


Active - Partially Closed to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list